RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients

BACKGROUND: Breast cancer patients treated with aromatase inhibitors (AIs) may experience musculoskeletal adverse events (MS-AEs). Several studies have confirmed that the RANKL/RANK/OPG signaling pathway plays a dominant role in bone health. Therefore, this study aimed to analyze the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jingxuan, Lu, Kangping, Song, Ying, Zhao, Shu, Ma, Wenjie, Xuan, Qijia, Tang, Dabei, Zhao, Hong, Liu, Lei, Zhang, Qingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547828/
https://www.ncbi.nlm.nih.gov/pubmed/26218592
http://dx.doi.org/10.1371/journal.pone.0133964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547828/
https://www.ncbi.nlm.nih.gov/pubmed/26218592
http://dx.doi.org/10.1371/journal.pone.0133964

Ejemplares similares